1 |
2% sodium chondroitin sulfate |
Chondroitin sulfate |
1件: D00080 D00080 💬 |
- |
- |
226 1件: 226 💬 |
2 |
5% lidocaine/5 mg/ml 0.02% estradiol compound cream |
Estradiol |
11件: D00105 D00105, D00358 D00358, D01413 D01413, D01617 D01617, D01953 D01953, D02086 D02086, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065, D08127 D08127 💬 |
ESR1 7件: ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 12件: Adrenergic signaling in cardiomyocytes, Breast cancer, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway |
226 1件: 226 💬 |
3 |
Adalimumab |
Adalimumab |
1件: D02597 D02597 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
019 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬 |
4 |
Agn 203818 |
- |
- |
- |
- |
226 1件: 226 💬 |
5 |
Alkalinized lidocaine-heparin |
Heparin |
4件: D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A 6件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes 4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 1件: 226 💬 |
6 |
Amitriptyline |
Amitriptyline |
2件: D00809 D00809, D07448 D07448 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
078 4件: 78, 97, 226, 299 💬 |
7 |
Aqx-1125 |
AQX-1125 |
- |
- |
- |
226 1件: 226 💬 |
8 |
Aqx-1125 100 mg |
AQX-1125 |
- |
- |
- |
226 1件: 226 💬 |
9 |
Aqx-1125 200 mg |
AQX-1125 |
- |
- |
- |
226 1件: 226 💬 |
10 |
Asp3652 |
- |
- |
- |
- |
226 1件: 226 💬 |
11 |
Asp6294 |
- |
- |
- |
- |
226 1件: 226 💬 |
12 |
Bladder instillation with heparin/ lidocaine |
Heparin |
4件: D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A 6件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes 4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 1件: 226 💬 |
13 |
Bladder instillation with triamcinolone acetonide |
Triamcinolone |
5件: D00385 D00385, D00983 D00983, D00984 D00984, D00985 D00985, D06216 D06216 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
226 1件: 226 💬 |
14 |
Bladder instillation without triamcinolone acetonide |
Triamcinolone |
5件: D00385 D00385, D00983 D00983, D00984 D00984, D00985 D00985, D06216 D06216 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
226 1件: 226 💬 |
15 |
Bladder instillations |
- |
- |
- |
- |
226 1件: 226 💬 |
16 |
Botox |
- |
- |
- |
- |
002 6件: 2 , 6 , 13, 51, 149, 226 💬 |
17 |
Botox 200u in normal saline |
- |
- |
- |
- |
226 1件: 226 💬 |
18 |
Botulinum toxin a |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
013 4件: 13, 51, 149, 226 💬 |
19 |
Buckwheat |
Buckwheat |
- |
- |
- |
226 1件: 226 💬 |
20 |
Bupivacaine |
Bupivacaine |
2件: D01450 D01450, D07552 D07552 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
046 8件: 46, 51, 53, 70, 96, 168, 226, 298 💬 |
21 |
Cannabidiol |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 17件: 6 , 8 , 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 226, 271 💬 |
22 |
Cannabidiol vaginal suppository |
Cannabidiol |
1件: D10915 D10915 💬 |
CNR1 2件: CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction 4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
226 1件: 226 💬 |
23 |
Capsaicin |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
002 5件: 2 , 6 , 19, 86, 226 💬 |
24 |
Certolizumab pegol |
Certolizumab pegol |
1件: D03441 D03441 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
037 6件: 37, 46, 96, 97, 226, 271 💬 |
25 |
Chondroitin sulfate |
Chondroitin sulfate |
1件: D00080 D00080 💬 |
- |
- |
096 2件: 96, 226 💬 |
26 |
Ciclosporin |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
026 13件: 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 💬 |
27 |
Ciklosporin |
- |
- |
- |
- |
226 1件: 226 💬 |
28 |
Combination product: hyperbaric oxygen therapy- |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
226 1件: 226 💬 |
29 |
Cyclosporine |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 35件: 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 63, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 💬 |
30 |
Device: interferential current |
- |
- |
- |
- |
226 1件: 226 💬 |
31 |
Device: intermittent exposure to oxygen via oro-nasal mask |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
226 1件: 226 💬 |
32 |
Dexmedetomidine |
Dexmedetomidine |
2件: D00514 D00514, D01205 D01205 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
002 12件: 2 , 4 , 6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬 |
33 |
Dimethyl sulfoxide |
Dimethyl sulfoxide |
1件: D01043 D01043 💬 |
- |
- |
226 1件: 226 💬 |
34 |
Dmso |
Dimethyl sulfoxide |
1件: D01043 D01043 💬 |
- |
- |
226 1件: 226 💬 |
35 |
Dmso cocktail |
Dimethyl sulfoxide |
1件: D01043 D01043 💬 |
- |
- |
226 1件: 226 💬 |
36 |
Erb-041 |
- |
- |
- |
- |
046 3件: 46, 96, 226 💬 |
37 |
Estradiol |
Estradiol |
8件: D00105 D00105, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 2件: ESR1, ESR2 💬 |
Breast cancer 9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
013 5件: 13, 46, 49, 226, 299 💬 |
38 |
Fospropofol |
Fospropofol |
1件: D04257 D04257 💬 |
- |
- |
226 1件: 226 💬 |
39 |
Fospropofol (lusedra®) 10 |
Fospropofol |
1件: D04257 D04257 💬 |
- |
- |
226 1件: 226 💬 |
40 |
Fospropofol (lusedra®) 12 |
Fospropofol |
1件: D04257 D04257 💬 |
- |
- |
226 1件: 226 💬 |
41 |
Fospropofol (lusedra®) 6.5 |
Fospropofol |
1件: D04257 D04257 💬 |
- |
- |
226 1件: 226 💬 |
42 |
Fremanezumab |
Fremanezumab |
1件: D11055 D11055 💬 |
CALCA 1件: CALCA 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction |
124 2件: 124, 226 💬 |
43 |
Gefapixant |
Gefapixant |
1件: D11349 D11349 💬 |
P2RX3 1件: P2RX3 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Taste transduction |
085 2件: 85, 226 💬 |
44 |
Glycine |
Glycine |
1件: D00011 D00011 💬 |
- |
- |
035 5件: 35, 60, 86, 226, 299 💬 |
45 |
Gralise |
- |
- |
- |
- |
097 2件: 97, 226 💬 |
46 |
Heparin |
Heparin |
1件: D07510 D07510 💬 |
SERPINC1 1件: SERPINC1 💬 |
Complement and coagulation cascades 1件: Complement and coagulation cascades |
060 11件: 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 💬 |
47 |
Heparin & alkalinized lidocaine bladder instillation |
Heparin |
4件: D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A 6件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes 4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 1件: 226 💬 |
48 |
Hyaluronic acid |
Hyaluronic acid |
1件: D08043 D08043 💬 |
- |
- |
046 5件: 46, 53, 70, 226, 231 💬 |
49 |
Hyaluronic acid and chondroitin sulfate |
Chondroitin sulfate |
2件: D00080 D00080, D08043 D08043 💬 |
- |
- |
226 1件: 226 💬 |
50 |
Hyaluronic acid/chondroitin sulfate |
Chondroitin sulfate |
2件: D00080 D00080, D08043 D08043 💬 |
- |
- |
226 1件: 226 💬 |
51 |
Hydrogen |
Hydrogen |
- |
- |
- |
005 7件: 5 , 6 , 13, 17, 83, 97, 226 💬 |
52 |
Ic cocktail |
- |
- |
- |
- |
226 1件: 226 💬 |
53 |
Intravesical onabotulinumtoxina injection |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
226 1件: 226 💬 |
54 |
Ipd® (japanese tradename) |
- |
- |
- |
- |
226 1件: 226 💬 |
55 |
Ipd® (suplatast tosilate) |
- |
- |
- |
- |
226 1件: 226 💬 |
56 |
Jnj-42160443 |
- |
- |
- |
- |
226 1件: 226 💬 |
57 |
Ketorolac |
Ketorolac |
2件: D00813 D00813, D08104 D08104 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
070 2件: 70, 226 💬 |
58 |
Ketorolac tromethamine |
Ketorolac |
3件: D00396 D00396, D00813 D00813, D08104 D08104 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
226 1件: 226 💬 |
59 |
Krp-116d |
- |
- |
- |
- |
226 1件: 226 💬 |
60 |
Lidocaine |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 10件: 6 , 13, 34, 46, 51, 86, 168, 226, 231, 256 💬 |
61 |
Lidocaine releasing intravesical system - liris® |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
226 1件: 226 💬 |
62 |
Liposome encapsulated bont-a |
- |
- |
- |
- |
226 1件: 226 💬 |
63 |
Liposomes |
- |
- |
- |
- |
226 1件: 226 💬 |
64 |
Liris 400 mg |
- |
- |
- |
- |
226 1件: 226 💬 |
65 |
Liris low dose and liris high dose |
- |
- |
- |
- |
226 1件: 226 💬 |
66 |
Liris® |
- |
- |
- |
- |
226 1件: 226 💬 |
67 |
Liris® 400 mg |
- |
- |
- |
- |
226 1件: 226 💬 |
68 |
Low-dose naltrexone |
Naltrexone |
2件: D02095 D02095, D05113 D05113 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
69 |
Lp-08 20mg |
- |
- |
- |
- |
226 1件: 226 💬 |
70 |
Lp-08 80mg |
- |
- |
- |
- |
226 1件: 226 💬 |
71 |
Metoprolol |
Metoprolol |
3件: D00601 D00601, D02358 D02358, D05011 D05011 💬 |
ADRB1 1件: ADRB1 💬 |
Adrenergic signaling in cardiomyocytes 10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
017 6件: 17, 57, 58, 113, 193, 226 💬 |
72 |
Metoprolol tartrate oral tablet |
Metoprolol |
3件: D00601 D00601, D02358 D02358, D05011 D05011 💬 |
ADRB1 1件: ADRB1 💬 |
Adrenergic signaling in cardiomyocytes 10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
73 |
Mirabegron |
Mirabegron |
1件: D09535 D09535 💬 |
ADRB3 1件: ADRB3 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
006 3件: 6 , 13, 226 💬 |
74 |
Mmf |
- |
- |
- |
- |
013 13件: 13, 35, 40, 49, 50, 51, 60, 65, 66, 222, 224, 226, 299 💬 |
75 |
Mn-001 |
- |
- |
- |
- |
226 1件: 226 💬 |
76 |
Mn-001 bid |
- |
- |
- |
- |
226 1件: 226 💬 |
77 |
Mr-mc-01 |
- |
- |
- |
- |
226 1件: 226 💬 |
78 |
Mycofenolate mofetil (mmf) |
- |
- |
- |
- |
226 1件: 226 💬 |
79 |
Mycophenolate |
Mycophenolic acid |
1件: D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 34件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
80 |
Mycophenolate mofetil |
Mycophenolate mofetil |
4件: D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 32件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 |
81 |
Naloxone |
Naloxone |
2件: D01340 D01340, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 2件: 6 , 226 💬 |
82 |
Naloxone hydrochloride |
Naloxone |
2件: D01340 D01340, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
83 |
Naltrexone |
Naltrexone |
2件: D02095 D02095, D05113 D05113 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 12件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬 |
84 |
Normal saline |
- |
- |
- |
- |
006 16件: 6 , 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 276, 296, 299 💬 |
85 |
Normal saline instillation |
- |
- |
- |
- |
226 1件: 226 💬 |
86 |
Nortriptyline |
Nortriptyline |
2件: D00816 D00816, D08288 D08288 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 226 💬 |
87 |
Omalizumab |
Omalizumab |
1件: D05251 D05251 💬 |
FCER1A 1件: FCER1A 💬 |
Asthma 4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
046 7件: 46, 53, 65, 98, 162, 226, 299 💬 |
88 |
Onabotulinum toxin a |
- |
- |
- |
- |
226 1件: 226 💬 |
89 |
Onabotulinumtoxin a |
- |
- |
- |
- |
051 2件: 51, 226 💬 |
90 |
Onabotulinumtoxina |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
006 3件: 6 , 13, 226 💬 |
91 |
Other: hyperbaric oxygen therapy |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
097 2件: 97, 226 💬 |
92 |
Other: inactive drug |
- |
- |
- |
- |
226 1件: 226 💬 |
93 |
Other: normal saline |
- |
- |
- |
- |
013 4件: 13, 222, 226, 280 💬 |
94 |
Other: saline as a nasal spray |
- |
- |
- |
- |
226 1件: 226 💬 |
95 |
Oxn 10/5 mg pr |
- |
- |
- |
- |
226 1件: 226 💬 |
96 |
Oxn 20/10 mg pr |
- |
- |
- |
- |
226 1件: 226 💬 |
97 |
Oxn 5/2.5 mg pr |
- |
- |
- |
- |
226 1件: 226 💬 |
98 |
Oxycodone |
Oxycodone |
3件: D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 7件: 6 , 13, 46, 70, 226, 231, 298 💬 |
99 |
Oxycodone hydrochloride |
Oxycodone |
3件: D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 4件: 6 , 70, 226, 298 💬 |
100 |
Oxycodone naloxone prolonged release tablets |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
101 |
Oxycodone/naloxone prolonged release t |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
102 |
Oxycodone/naloxone prolonged release tablets 10/5 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
103 |
Oxycodone/naloxone prolonged release tablets 20/10 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
104 |
Oxycodone/naloxone prolonged release tablets 5/2.5 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
105 |
Oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
006 18件: 6 , 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 294, 299, 330 💬 |
106 |
Oxytocin |
Oxytocin |
1件: D00089 D00089 💬 |
OXTR 1件: OXTR 💬 |
Calcium signaling pathway 4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
006 5件: 6 , 127, 193, 206, 226 💬 |
107 |
Pd 0299685 |
- |
- |
- |
- |
226 1件: 226 💬 |
108 |
Pd 0299685 at 15mg bid |
- |
- |
- |
- |
226 1件: 226 💬 |
109 |
Pd 0299685 at 30mg bid |
- |
- |
- |
- |
226 1件: 226 💬 |
110 |
Pd-0299685 |
PD-0299685 |
- |
- |
- |
226 1件: 226 💬 |
111 |
Pentosan polysulfate |
Pentosan polysulfate |
1件: D05428 D05428 💬 |
- |
- |
019 3件: 19, 26, 226 💬 |
112 |
Pentosan polysulfate sodium 100 mg |
Pentosan polysulfate |
1件: D05428 D05428 💬 |
- |
- |
226 1件: 226 💬 |
113 |
Pf-04383119 |
- |
- |
- |
- |
226 1件: 226 💬 |
114 |
Placebo |
- |
- |
- |
- |
003 26件: 3 , 5 , 6 , 13, 14, 37, 40, 46, 49, 50, 51, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 💬 |
115 |
Platelet enriched plasma |
- |
- |
- |
- |
226 1件: 226 💬 |
116 |
Platelet-rich plasma |
- |
- |
- |
- |
226 1件: 226 💬 |
117 |
Procedure: injections on posterior bladder wall excluding the trigone |
- |
- |
- |
- |
226 1件: 226 💬 |
118 |
Procedure: injections upper aspect of trigone of urinary bladder |
- |
- |
- |
- |
226 1件: 226 💬 |
119 |
Procedure: pelvic floor physical therapy |
- |
- |
- |
- |
226 1件: 226 💬 |
120 |
Procedure: sham cystoscopy procedure |
- |
- |
- |
- |
226 1件: 226 💬 |
121 |
Procedure: urodynamic study |
- |
- |
- |
- |
226 1件: 226 💬 |
122 |
Prograf |
- |
- |
- |
- |
060 3件: 60, 222, 226 💬 |
123 |
Propiverine |
Propiverine |
1件: D08441 D08441 💬 |
CACNA1C 9件: CACNA1C, CACNA1D, CACNA1F, CACNA1S, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Adrenergic signaling in cardiomyocytes 42件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Regulation of actin cytoskeleton, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
124 |
Propiverine hydrochloride |
Propiverine |
1件: D08441 D08441 💬 |
CACNA1C 9件: CACNA1C, CACNA1D, CACNA1F, CACNA1S, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Adrenergic signaling in cardiomyocytes 42件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Regulation of actin cytoskeleton, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
125 |
Rimso 50 |
- |
- |
- |
- |
226 1件: 226 💬 |
126 |
Rn624, ri624 |
- |
- |
- |
- |
226 1件: 226 💬 |
127 |
Sandimmun |
- |
- |
- |
- |
097 2件: 97, 226 💬 |
128 |
Sandimmun neoral |
- |
- |
- |
- |
060 3件: 60, 97, 226 💬 |
129 |
Si-722 |
- |
- |
- |
- |
226 1件: 226 💬 |
130 |
Sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 17件: 6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬 |
131 |
Sulfate |
Sulfate ion |
- |
- |
- |
002 25件: 2 , 6 , 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 222, 226, 265, 296, 297, 299 💬 |
132 |
Suplatast tosilate |
- |
- |
- |
- |
226 1件: 226 💬 |
133 |
Tacrolimus |
Tacrolimus |
2件: D00107 D00107, D08556 D08556 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
002 32件: 2 , 6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 |
134 |
Tanezumab |
Tanezumab |
1件: D09387 D09387 💬 |
NGF 1件: NGF 💬 |
Apoptosis 9件: Apoptosis, Calcium signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
226 2件: 226, 298 💬 |
135 |
Targinact 10 mg/5 mg prolonged-release tablets |
- |
- |
- |
- |
006 2件: 6 , 226 💬 |
136 |
Targinact 20mg/10 mg prolonged-release tablets |
- |
- |
- |
- |
226 1件: 226 💬 |
137 |
Targinact 5mg/2.5 mg prolonged-release tablets |
- |
- |
- |
- |
226 1件: 226 💬 |
138 |
Tramadol |
Tramadol |
2件: D01355 D01355, D08623 D08623 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 5件: 46, 70, 78, 226, 271 💬 |
139 |
Triamcinolone |
Triamcinolone |
5件: D00385 D00385, D00983 D00983, D00984 D00984, D00985 D00985, D06216 D06216 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
035 8件: 35, 46, 56, 70, 90, 96, 226, 298 💬 |
140 |
Tromethamine |
Tromethamine |
1件: D00396 D00396 💬 |
- |
- |
226 1件: 226 💬 |
141 |
Tti-1612 |
- |
- |
- |
- |
226 1件: 226 💬 |
142 |
Urg101 |
- |
- |
- |
- |
226 1件: 226 💬 |
143 |
Water |
Water |
1件: D00001 D00001 💬 |
- |
- |
002 22件: 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
144 |
Ym672 |
- |
- |
- |
- |
226 1件: 226 💬 |
145 |
Ym672 (ipd®) |
- |
- |
- |
- |
226 1件: 226 💬 |